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Abstract
Single nucleotide polymorphisms (SNPs) of the tumour necrosis factor alpha (TNFα) gene (TNFA) have 
been extensively studied and shown to be associated with an increased risk of the development of 
various chronic inflammatory diseases. Inflammation has been demonstrated to play a central role in the 
pathogenesis of chronic rhinosinusitis (CRS), and TNFα is a key pro-inflammatory cytokine with important 
functions in these processes. In order to determine whether the well-known TNFA –308 G>A SNP has a 
role in a genetic predisposition to CRS in the Hungarian population, we analyzed our genomic collection 
containing control and CRS patient samples in a case–control study, and compared the genotype and 
allele frequencies. There was no significant difference in the observed genotype or allele frequencies 
between the controls and the total CRS group. However, after careful stratification of the patient group 
on the basis of the observed clinical symptoms, we found a significantly higher carriage rate of the rare 
A allele-containing genotypes among the CRS patients with nasal polyposis (NP) who also exhibited 
sensitivity to aspirin (acetylsalicylic acid, ASA+). It is concluded that genetic variants of the TNFA gene 
may affect the risk of CRS in a clinically well-defined group of CRSNP+ASA+ patients in the Hungarian 
population. Our results also emphasize that the group of CRS patients is not homogenous in that patients 
exhibiting different clinical symptoms exist. Their carried genetic predisposing factors, and as a result, the 
exact molecular events leading to the development of various forms of CRS, may also differ.
Keywords:  chronic rhinosinusitis, nasal polyposis, single nucleotide polymorphism, TNFA –308 G>A
Introduction
Chronic rhinosinusitis (CRS) is characterized by persistent 
inflammation of the nasal and paranasal mucosa (1). CRS is 
present when any combination of the major symptoms, including 
nasal congestion or blockage, loss of smell, rhinorrhoea, post-
nasal drip and facial pain or pressure occurs for an extended 
period of time (over 12 weeks) despite various treatment 
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attempts. It is a clinically heterogeneous disease frequently 
associated with other airway diseases, such as asthma, allergy, 
chronic obstructive pulmonary disease and bronchiectasis (2–6).
Nasal polyposis (NP) is characterized by non-granulomatous 
inflammatory tissue extensions of the mucosal surface lining 
the sinonasal cavities (7). CRS can occur either with (CRSNP+) 
or without (CRSNP−) the appearance of NP. A special group of 
CRSNP+ patients exhibits a marked sensitivity to aspirin (ace-
tylsalicylic acid, ASA) or other non-steroidal anti-inflammatory 
drugs. In such sensitive individuals (ASA+), consumption of 
even a small dose of ASA can cause bronchiolar constriction, 
rhinorrhoea and shock symptoms related to a non-IgE-medi-
ated pharmacological hypersensitivity reaction (8–10).
The pathogenesis of CRS is a complex process in which 
several self and environmental factors have been implicated 
(1, 11). Anatomic features of the upper airway that cause 
mucous stagnation inside the sinuses, bacterial and fungal 
infections and abnormal immune regulation have been shown 
to play an important role in the pathogenesis of the disease 
(12–14). Apart from these, individual genetic factors have a 
significant role in making certain individuals susceptible to 
the development of CRS (15, 16).
Aberrant immune regulation often results in chronic inflam-
mation, thus the different molecules (cytokines, chemokines 
and anti-microbial peptides) that are playing an important 
role in these processes have been suggested to be involved 
the pathogenesis of CRS, too. One such candidate is the pro-
inflammatory cytokine tumour necrosis factor alpha (TNFα), 
the presence of which has already been detected in various 
cellular components of the polypoid tissues of CRS patients 
(17, 18). This has led to the suggestion that genetic polymor-
phisms affecting the regulation and/or function of the gene 
encoding the TNFα cytokine (TNFA) may play important roles 
in the genetic predisposition to CRS (19, 20).
The TNFA locus is located within the highly polymorphic 
major histocompatibility III region on chromosome 6 (6p21.3). 
There are many single nucleotide polymorphisms (SNPs) 
within this gene, especially in its 5′ regulatory region, often 
exhibiting associations with the pathogenesis of certain 
chronic inflammatory and immune-mediated diseases (21). 
One of them, the TNFA –308 G>A (rs1800629) is a relatively 
frequent SNP in Caucasian populations, which have already 
been investigated in the context of CRS (22–25). The results 
of these studies led to the postulation of a correlation between 
the carriers of the rare A allele and CRS, and also CRSNP+, 
in Turkish and US Caucasian populations, whereas the same 
association was not detected in Canadian individuals.
In order to establish whether the TNFA –308 G>A SNP is 
involved in a genetic predisposition to CRS in the Hungarian 
population, we performed case–control genetic studies. Our 
results indicate that the rare A allele, or alternatively, a link-
age group carrying this allele may be a genetic predispos-
ing factor in the Hungarian population, but this association is 
restricted to the ASA+ group of CRSNP+ patients.
Methods
Study population and ethics
Buccal swab samples were obtained from a total of 544 
Caucasian individuals (169 controls and 375 patients) from 
various otorhinolaryngology centres in Hungary (University of 
Szeged; Semmelweis University, Budapest; Pécs University; 
Borsod-Abaúj-Zemplén County Hospital and University 
Teaching Hospital, Miskolc; and St John’s and North-Buda 
Hospitals of the Municipality of Budapest). The ages of the 
recruited individuals were between 18 and 72 years. Patients 
were selected after trained medical professionals had estab-
lished the diagnosis of CRS. Exclusion criteria included the 
presence of signs of acute upper airway infection, known 
malignancy or any other general disease, infectious dis-
ease, primary or acquired immune deficiency, dialysis, any 
chronic autoimmune diseases, rhinitis medicamentosa or 
odontogenic sinusitis. The control group comprised individu-
als without any medical history of CRS and with none of the 
above-described diseases and conditions.
The study was approved by the Hungarian Research 
Ethics Committee. All participating subjects gave their written 
consent before sample collection. The study was performed 
in accordance with the principles stated in the Declaration of 
Helsinki and its later revisions.
Polymorphism analysis
Genomic DNA was obtained from buccal swab samples 
by using the QIAGEN EZ1 DNA Investigator Kit (QIAGEN, 
Germany).
Patient and control samples were genotyped for the TNFA 
-308 G>A (rs1800629) SNP by the PCR-RFLP (Restriction 
Fragment Length Polymorphism) method, as described 
previously (26). Briefly, a short 106-bp genomic sequence 
around the –308 position of the TNFA promoter was ampli-
fied by using the following primers: 5′-GAG GCA ATA GGT 
TTT GAG GGG CAT-3′ and 5′-GGG ACA CAC AAG CAT CAA 
GG-3′. Restriction analysis of the resulting fragments was per-
formed with an NcoI enzyme (Fermentas, Vilnius, Lithuania). 
Electrophoresis of the digested PCR products was performed 
on a 2% agarose gel (Lonza, Rockland, ME, USA). To visualize 
DNA fragments, gels were stained with GelRed (Biotium, Inc., 
Hayward, CA, USA).
Statistical analysis
Statistical analysis was carried out on the various groups of 
patients and controls according to the rules of case–control 
allelic association study designs. Genotype and allele fre-
quencies were calculated by determining the percentage 
of individuals carrying the different genotypes and the per-
centage of carried alleles in each group. For the statistical 
analyses, the dominant genotype model was applied, where 
the group of rare-allele carriers (GA + AA) was compared 
with the group of non-carriers (GG). Statistical significance 
of the associations, odds ratios (ORs) and their 95% confi-
dence intervals (CIs) were calculated using the SPSS soft-
ware (Version 17, SPSS, Chicago, IL, USA).
Hardy–Weinberg equilibrium (HWE) was calculated using 
a web-based calculator (http://www.oege.org/software/hwe-
mr-calc.shtml) (27).
Literature search
A PubMed search was performed and all the currently avail-
able reports investigating the possible relationship between 
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CRS (with or without NP) and the TNFA -308 G>A SNP in dif-
ferent populations were reviewed.
Results
Demographic analysis
The clinical characteristics of the study participants are pre-
sented in Table 1. Altogether 169 controls (84 males and 85 
females) and 375 CRS patients (204 males and 171 females) 
were genotyped for the TNFA –308 G>A SNP. The mean 
ages of the controls and the cases were 43.1 and 48.8 years, 
respectively. Aspirin sensitivity (ASA+) was detected in 18.4% 
(n = 60) of the CRSNP+ patients. None of the controls was 
aware of ASA sensitivity (Tables 1 and 2). We also analyzed 
whether our study population was in HWE for the studied 
genetic variant. We did not detect any deviation from the 
HWE neither in the controls nor in our patient group (Table 1).
Genetic analysis of the TNFA –308 G>A SNP in the 
unstratified and stratified groups of CRS patients
The observed genotype and allele frequencies of the TNFA 
–308 G>A SNP are presented in Supplementary Table  1, 
available at International Immunology Online. The genotype 
distribution of the SNP did not exhibit a statistically significant 
difference as compared with the unstratified group of CRS 
patients (n = 375) and the controls (n = 169) (Pearson chi-
square test 2×2 table, P = 0.54). Similar results were obtained 
by comparing the allele frequencies in the groups of controls 
and patients.
Next, we stratified the CRS group according to the pres-
ence or absence of NP (Fig. 1 and Supplementary Table 2, 
available at International Immunology Online). We did not 
detect a statistically significant difference as concerns 
the observed genotype and allele frequencies in either the 
CRSNP− (n = 49) or the CRSNP+ (n = 326) cohort relative to 
the controls (n  =  169) (Pearson chi-square test 2×2 table, 
P = 0.45 and P = 0.39, respectively).
Finally, we stratified the CRSNP+ group to cohorts of patients 
on the basis of their ASA tolerance (CRSNP+ASA−, n = 266; and 
CRSNP+ASA+, n = 60) (Fig. 1). The analysis revealed statisti-
cally significant differences in the distributions of various geno-
type and allele frequencies between the CRSNP+ASA+ and 
control groups (Pearson chi-square test 2×2 table, P  =  0.03 
and P = 0.04, respectively) (Table 3). Thus, our data indicated 
that the rare A allele was positively associated exclusively with 
the development of CRS and NP in the ASA+ patients as the 
OR for this complex disease was twice as high in individuals 
who carried the minor A allele in at least one copy (OR = 2.0, 
at 95% CI: 1.1–3.7 when the observed genotype frequencies 
were compared and OR = 1.7, at 95% CI: 1.0–2.9 when the 
allele frequency data were analysed).
Comparison of the results of independent studies 
analysing the role of the TNFA –308 G>A SNP in various 
ethnic populations
Next, we performed a literature search and selected all 
the available reports that investigate the possible relation-
ship between CRS (with or without NP) and the TNFA –308 
G>A SNP in different populations (22–25), and compared 
our data with the results of such investigations (Table  4). 
There had been four previous analyses of the association 
of the TNFA –308 G>A SNP and CRSNP+. Three studies 
reported an association between these symptoms and the 
rare A  allele of the analysed SNP, whereas a study on a 
Canadian population did not. In agreement with the lat-
ter, we did not detect statistically significant differences 
Table 1. Demographic data of the study population
Demographic 
parameters
Controls (n = 169) CRS (n = 375)
Mean age (years) 43.1 (18–69) 48.8 (18–78)
χ2 (P value)a P < 0.05
Sex (M/F)
 n (%)/n (%) 84 (49.7)/85 (50.3) 204 (54.4)/171 (45.6)
 χ2 (P value)a n.s.
ASA sensitivity
 n (%) 0 (0) 60 (16.0)
 χ2 (P value)a P < 0.05
HWEb for the  
TNFA –308 G>A SNP
n.s. n.s.
n.s., statistical comparison was not significant (P > 0.05).
aChi-square analysis with the Pearson correction. bDeviation from the 
Hardy–Weinberg equilibrium.
Table 2. Stratification of the CRS patient group
CRSNP− (n = 49) CRSNP+ (n = 326) CRSNP+ASA− (n = 266) CRSNP+ASA+ (n = 60)
Mean age (years) 48.2 (22–78) 49.1 (18–78) 49.0 (18–77) 46.7 (23–77)
χ2 (P value)a n.s. n.s.
Sex (M/F)
 n (%)/n (%) 27 (55.1)/22 (44.9) 182 (55.8)/144 (44.1) 158 (59.4)/108 (40.6) 24 (40.0)/36 (60.0)
 χ2 (P value)a n.s. P < 0.05
ASA sensitivity
 n (%) 0 (0) 60 (18.4) 0 (0) 60 (100)
 χ2 (P value)a P < 0.05 P < 0.05
CRSNP+/−, chronic rhinosinusitis occurring with (+) or without (−) nasal polyposis, respectively; CRSNP+ASA+/ASA−, chronic rhinosinusitis occur-
ring with nasal polyposis and with (+) or without (−) aspirin sensitivity; n.s., the result of the statistical comparison is not significant (P > 0.05).
aChi-square analysis with the Pearson correction.
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when the distributions of various genotypes and alleles 
were compared in the control and the overall CRS patient 
groups, nor when we performed the analysis on the control 
and CRSNP+ groups.
We also assessed the frequencies of ASA+ patients 
within the CRSNP+ cohorts in the previous studies. In the 
Canadian and one of the Turkish studies, this group was 
relatively numerous (38.8 and 34.0%, respectively), whereas 
in our case, the proportion of ASA+ patients (18.4%) was 
more similar to the data reported on the US Caucasians 
(16.4%) and the other cohort of Turkish patients (14.6%). 
This may reflect differences in the inclusion criteria applied 
to select the patient and control cohorts from the different 
populations.
We also noted that the frequencies of rare A allele-containing 
genotypes varied greatly in the controls of the different ethnic 
groups, which was in agreement with previous, similar case–
control investigations. Moreover, one of the Turkish studies 
did not mention whether the studied cohort was in HWE (22), 
whereas the other Turkish study could not demonstrate HWE 
within their controls (24).
Discussion
CRS is a multifactorial disease of unknown etiology (28) in 
which yet undefined external and internal factors initiate innate 
and adaptive immune responses in the sinonasal cavities (1, 
14, 16). During these processes, elevated expressions of vari-
ous cytokines (e.g. TNFα and IL-1) play important roles (17, 
18), e.g. in the initiation of local inflammation, a process of great 
importance during the clearance of attacking pathogens (29, 
30). However, the extensive activation of these mechanisms 
Fig. 1. Stratification of the CRS group (n = 375) was performed on the basis of the clinical symptoms exhibited by the patients. At the first 
level, we grouped the patient cohort on the basis of the absence (NP−, n = 49) or presence (NP+, n = 326) of NP. The latter group was sub-
sequently divided into groups of patients with (ASA+, n = 60) or without (ASA−, n = 266) aspirin sensitivity. A statistically significant difference 
was detected in the distribution of the rare A allele-containing genotypes only when the CRSNP+ASA+ group of patients was compared with 
the controls.
Table 3. Genotype- and allele-frequencies of the TNFA –308 G>A SNP in the control individuals and the groups of CRSNP+ 
patients (ASA+ and ASA−)
Controls  
n (%)
CRSNP+ASA−  
n (%)
χ2 (P value)a  
ORb (95% CI)
CRSNP+ASA+  
n (%)
χ2 (P value)a 
ORb (95% CI)
χ2 (P value)a 
ORb (95% CI)
TNFα –308 G>A 169 266 60
Genotype frequency
 GG 122 (72.2) 189 (71.0) 0.79c 34 (56.7) 0.03d 0.03e
 GA 41 (24.3) 68 (25.6) 1.1 (0.7–1.6) 23 (38.3) 2.0 (1.1–3.7) 1.9 (1.1–3.3)
 AA 6 (3.5) 9 (3.4) 3 (5.0)
Allele frequency
 G 285 (84.3) 446 (83.8) 0.84c 91 (75.8) 0.04d 0.04e
 A 53 (15.7) 86 (16.2) 1.0 (0.7–1.5) 29 (24.2) 1.7 (1.0–2.9) 1.7 (1.0–2.9)
CRSNP+ASA+/ASA−, chronic rhinosinusitis occurring with nasal polyposis and with (ASA+) or without (ASA−) aspirin sensitivity.
aChi-square analysis with the Pearson correction. bThe OR for the combination of both homozygote and heterozygote carriers of the minor alleles 
was determined in comparison with that for homozygote carriers of the common alleles. cStatistical analysis was done comparing the control 
and the CRSNP+ASA− groups. dStatistical analysis was done comparing the control and the CRS NP+ASA+ groups. eStatistical analysis was done 
comparing the CRSNP+ASA− and CRSNP+ASA+ groups. Bold text indicates values that are significant at the 0.05 level.
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can also result in the establishment of chronic inflammation 
and the subsequent development of NP.
Hereditable genetic factors appear to be important in the 
genetic predisposition to CRS (15, 16), and it was also pro-
posed in the literature that polymorphisms that participate in 
the regulation and/or function of pro-inflammatory cytokines 
may be involved in the pathogenesis of the disease. In this 
respect, polymorphisms of the promoter region of the TNFA 
locus have already been analyzed in Turkish (22, 24), Canadian 
(25) and US Caucasian (23) individuals, with special attention 
to the –308 G>A SNP. The results of these investigations are 
conflicting, however, for reasons that are currently unknown.
In order to investigate whether the well-known and rela-
tively frequent TNFA –308 G>A promoter polymorphism 
predisposes carrier individuals to the development of CRS 
in the Hungarian population, we performed a case–con-
trol study to compare the frequencies of various genotypes 
and alleles in control individuals and in CRS patients. The 
results of the previous studies combined with our data led 
us to categorize our patients into clinically more homogene-
ous subgroups. Detailed analysis of these indicated that the 
proportion of individuals carrying the rare A  allele differed 
between the controls and the CRSNP+ASA+ group (P = 0.03 
in the comparison of the genotypes and P = 0.04 for the allele 
frequencies), and also comparing the CRSNP+ASA− versus 
the CRSNP+ASA+ groups (P = 0.03 in the comparison of the 
genotypes and P  =  0.04 for the allele frequencies). These 
data suggest that the CRSNP+ASA+ subgroup is a genetically 
unique entity within the group of CRS patients, at least in the 
studied Hungarian population, in which the rare A allele of the 
studied TNFA –308 SNP can be regarded as a genetic sus-
ceptibility factor. This correlates well with the available clini-
cal data, suggesting that this cohort of patients is a clinically 
distinct group that often demonstrates extreme resistance to 
therapy and in whom the incidence of relapses after surgical 
removal of the polypoid tissues is very high.
Next, we compared our results with the already published 
data, investigating the role of the TNFA –308 SNP in the genetic 
predisposition to CRS in different populations (22–25), but this 
turned out to be somewhat challenging. The reason, however, 
for the differences is not clear. Differences in study design and 
selection criteria utilized to recruit patients and controls can 
offer only a partial explanation. Another important factor to 
be considered is the ethnicity of the study populations. It has 
been noted earlier both by ourselves and by other research-
ers that the frequency of the rare A allele-containing genotypes 
varies greatly already in the general population in different eth-
nic groups (31, 32). Discrepancies can also be observed with 
regard to whether a given –308 A allele predisposes the carrier 
individuals to the same diseases in different ethnic populations 
(31, 32). Thus, comparison of all these data with our current 
results strongly argues for the need of multicentric, systematic 
clinical and/or genetic investigations performed according to 
consensus patients’ inclusion/exclusion criteria. Such investi-
gations would help us to identify clear population-related differ-
ences, e.g. in the percentage of NP+ or ASA+ individuals among 
the CRS cohort or in the inherited genetic predisposing or pro-
tective factors.
The differences observed in various studies of CRS can for-
mally also suggest that it is maybe not the A allele of the TNFA 
–308 G>A SNP itself that is responsible for the observed asso-
ciations. Alternatively, an extended linkage group on the short 
arm of chromosome 6 around the TNFA locus may rather be 
responsible for the genetic predisposition to the investigated 
disease. This, together with the existence of population-spe-
cific linkage groups, could explain the observed population-
related differences.
In our study, the gathered clinical and genetic data suggest 
that the overall group of CRS patients is indeed heterogene-
ous. Many differences have been described in the clinical 
characteristics of these patients (severity of inflammation, 
sensitivity to ASA), and severe cases often exhibit extreme 
treatment resistance and the recurrence of symptoms after 
the surgical resection of polypoid tissues. All these data sug-
gest that not only the genetic predisposing factors but also 
the actual disease pathogenesis at the molecular level may 
differ in the various CRS subgroups.
Limitations of the current study arise from the moderate 
size of the cohort that was used for the analyses (169 controls 
and 375 CRS patients). We believe, however, that in the era of 
robust genome-wide association studies carefully designed 
classical case–control studies of such moderately sized study 
cohorts can still have their significance. Such targeted stud-
ies can investigate the relevance of the observed associa-
tions reported by large-scale analyses. Also, because of their 
relative ease and less cost-effective nature they can be used 
to detect population-related differences, as well as discover 
special cohorts within larger patient groups differ in terms of 
Table 4. Comparative analysis of the previously published genetic studies investigating the association of the TNFA –308 G>A 
SNP and CRS
Percent of GA+AA  
in controls
Percent of ASA+ in CRSNP+ 
patients
Association 
detected
Controls in HWE Analysed 
population
Authors
21.7% 14.6% Yes No Turkish Erbek (2007) (24)
11.5% 16.4% Yes Yes US Caucasian Bernstein (2009) (23)
— 38.8%a No Yes Canadian Mfuna-Endam (2010) (25)
6.7% 34.0% Yes No data Turkish Batikhan (2010) (22)
27.8% 18.4% Yesb Yes Hungarian Present data
ASA+, aspirin sensitivity; CRSNP+, chronic rhinosinusitis occurring with nasal polyposis.
aEstimated value based on the reported proportions of NP+ and ASA+ patients in the overall CRS cohort. bAssociation was detected only 
between the rare A allele and the ASA+ group of CRSNP+ patients.
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the exact disease pathogenesis. Information gathered from 
such studies can be used to develop more sophisticated 
patient inclusion/exclusion criterion systems in order to gen-
erate homogenous study groups for future high-throughput 
analyses.
Supplementary data
Supplementary data are available at International Immunology 
Online.
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